Latest Rosiglitazone Stories

2009-06-10 07:00:00

LOS ALTOS, Calif., June 10 /PRNewswire/ -- InteKrin Therapeutics Inc presented Phase 2a clinical study results at the American Diabetes Association annual meeting in New Orleans demonstrating that once a day oral treatment with INT131 provides anti-diabetic efficacy consistent with maximal dose thiazolidinedione (TZD) therapy but with less hematocrit reduction and weight gain. The 4 week double blind placebo controlled study of INT131 in Type 2 Diabetes Mellitus (T2DM) patients previously...

2009-06-08 10:30:00

U.S. researchers said on Sunday that diabetics with stable heart disease do just as well taking drugs alone as getting quick angioplasty or bypass surgery to open blocked heart arteries, Reuters reported.The report said heart patients could safely wait and give drugs a chance to work, rather than immediately undergoing angioplasty and a heart stent to restore blood flow and ease chest pain.However, it acknowledged that patients with more severe disease sent for more invasive heart bypass...

2009-06-08 05:22:00

FRANKLIN LAKES, N.J., June 8, /PRNewswire-FirstCall/ -- Research presented at the American Diabetes Association's 69th Scientific Sessions points to increased risk for people with diabetes associated with two widely used drug classes; while another study shed new light on a different class of drugs that faced increased scrutiny from the US Food and Drug Administration (FDA). Researchers from Medco Health Solutions, Inc. (NYSE: MHS) today released the results of a number of studies that will...

2009-06-05 16:15:00

RECORD trial also demonstrates durable blood sugar control over time with Avandia LONDON, RESEARCH TRIANGLE PARK, N.C., and NEW ORLEANS, June 5 /PRNewswire/ -- Clinical trial results presented today at the American Diabetes Association annual meeting show that overall rates of cardiovascular hospitalization and cardiovascular death are similar in patients taking Avandia (rosiglitazone) compared to those receiving metformin and sulfonylurea. Results from the 4,447-patient Rosiglitazone...

2009-06-05 07:00:00

Today's announcement hurts thousands of Avandia patients, counsel says HOUSTON, June 5 /PRNewswire/ -- Noted Houston trial lawyer Mark Lanier of The Lanier Law Firm says "useless trick science" is the basis for a new study being unveiled today in New Orleans by drug maker GlaxoSmithKline (NYSE: GSK) about the side effects caused by the company's diabetes medication Avandia, which reportedly has been linked to heart problems in thousands of patients. Mr. Lanier represents many former Avandia...

2009-05-28 07:00:00

LOS ALTOS, Calif., May 28 /PRNewswire/ -- InteKrin Therapeutics, Inc. announced today it will present Phase 2a clinical data for INT131, a Selective PPAR Modulator (SPPARM), at the American Diabetes Association annual meeting in New OrleansSaturday, June 6, 2009 during the "Novel Diabetes Therapies in Development in Humans" session at 4:00 pm CDT. Dr. Alex DePaoli, Chief Medical Officer of InteKrin Therapeutics, will provide a summary of the latest clinical data supporting the design of...

2009-05-15 09:45:00

- Welchol Added to Metformin Significantly Reduced A1C and LDL-C in Patients with Type 2 Diabetes - Open-Label Extension Study Demonstrated the Safety and Durability of Welchol for up to 78 Weeks of Treatment PARSIPPANY, N.J., May 15 /PRNewswire/ -- Daiichi Sankyo, Inc. (DSI) announced today that data from a 16-week, randomized, open-label pilot study demonstrated that Welchol(R) (colesevelam HCl) significantly improved glycemic control and reduced mean LDL cholesterol (LDL-C) when added to...

2009-05-14 12:02:00

BETHESDA, Md., May 14 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that, on May 12, 2009, its Board of Directors elected a new, independent Director, Thomas B. Peter, to begin serving immediately. Mr. Peter will also serve on the Company's Compensation and Nominating Committees....

2009-04-14 09:51:00

JACKSONVILLE, Fla., April 14 /PRNewswire-USNewswire/ -- When concerns were raised about the safety of the diabetes medication, rosiglitazone, in May 2007, many patients and their doctors made the decision to discontinue use of the drug. A study published today in Endocrine Practice by Dr. Etta Fanning from the University of Texas Health Science Center along with her colleagues reported that many patients who discontinued use of rosiglitazone received less therapy and higher blood glucose...

2009-04-02 14:35:37

 Treatment with the glitazone class of diabetes drugs leads to a "modest" increase in the risk of diabetic macular edema (DME)"”a common complication that can lead to vision loss, reports a study in the April issue of the American Journal of Ophthalmology (http://www.elsevier.com/locate/ajo), published by Elsevier.Using a database of about 170,000 patients with diabetes, Drs. Donald S. Fong and Richard Contreras of Southern California Permanente Medical Group analyzed the link...

Word of the Day
  • A murmuring sound; a rushing or whistling sound, like that of the wind; a deep sigh.
  • A gentle breeze; a waft; a breath.
  • Any rumor that engages general attention.
  • A cant or whining mode of speaking, especially in preaching or praying; the chant or recitative characteristic of the old Presbyterians in Scotland.
  • To make a rushing, whistling, or sighing sound; emit a hollow murmur; murmur or sigh like the wind.
  • To breathe in or as in sleep.
  • To utter in a whining or monotonous tone.
According to the OED, from the 16th century, this word is 'almost exclusively Scots and northern dialect until adopted in general literary use in the 19th.'